Recruiting
Phase 1

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Sponsor:

BrightGene Bio-Medical Technology Co., Ltd.

Code:

NCT06714955

Conditions

Non-diabetic Overweight or Obese

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information